MapLight Therapeutics, Inc. (MPLT)
NASDAQ • Healthcare
Last close at September 14, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Dec 3
in 79 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Next report — what to expect
MapLight Therapeutics, Inc. (MPLT) is scheduled to report earnings on September 18, 2026. Wall Street expects consensus EPS of -$1.349. The company has beaten EPS in 1 of its 4 most recent quarters, putting focus on any update that shifts expectations around near-term profitability.
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. develops clinical-stage biotechnology therapies for severe central nervous system disorders and trades on NASDAQ under the ticker MPLT. The company develops neuropsychiatric drug candidates from a proprietary platform designed to identify and modulate disease-linked neural circuits, and it operates as a subsidiary of Catalyst4, Inc.
Today's Snapshot
MPLT started the session slightly lower at 13.10, while its sector was flat. MPLT is due to report earnings on 18 September.
Trading Volume
Below 10d avg (514.0K)
28.3K
vs S&P 500 Today
Strong Underperformance
-4.51%
Updated: September 15, 2026 at 14:48 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$13.14 - $20.63Sell
- RSI (14)38.57Neutral
- Stochastic %K (14, 3, 3)55.16Neutral
- MACD Level (12, 26)-1.10Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.